ObjectiveTo observe the clinical efficacy and safety of thalidomide combined with technetium ［99Tc］methylenediphosphonate in patients with psoriatic arthritis. Methods60 cases of patients with psoriatic arthritis were treated with thalidomide combined with technetium ［99Tc］ methylenediphosphonate for 12 weeks. Observation of the clinical therapeutic effect of the patients. The clinical symptoms and signs, the changes in related laboratory test indexes of the patients before and after 12 weeks＇ treatment were compared. Observation of the occurrence of adverse reactions. ResultsAfter 12 weeks of treatment, the total effective rate of treatment was 98.33%. The PASI score, HAQ score, joint pressure index, and joint swelling index of the patients were significantly lower than those before the treatment (P＜0.01). The levels of erythrocyte sedimentation rate, C reactive protein, immunoglobulin A, immunoglobulin G and immunoglobulin M levels were significantly lower than those before treatment (P＜0.01). There was no serious adverse reaction during the treatment. ConclusionThalidomide combined with technetium ［99Tc］ methylenediphosphonate treatment in patients with psoriatic arthritis can get better clinical effect, improve the clinical symptoms, relieve the inflammatory response, and have high safety.

无